Pathophysiology of type 2 diabetes mellitus: Potential role of incretin-based therapies

R. Keith Campbell, Michael E. Cobble, Timothy S. Reid, Mansur E. Shomali

Research output: Contribution to journalReview article

Abstract

The multifactorial nature of the pathogenesis of T2DM provides an opportunity to combine treatments that act upon different mechanisms. In addition to improving insulin resistance and pancreatic β-cell dysfunction, the GLP-1 agonists and DPP-4 inhibitors improve the impaired incretin response, as well as increase insulin secretion and reduce glucagon secretion, both in a glucose-dependent manner. As a result of these multiple actions, the GLP-1 agonists and DPP-4 inhibitors lower both fasting and postprandial glucose levels. The effects of GLP-1 agonists tend to be greater, probably because they produce pharmacologic levels of GLP-1 compared to physiologic levels with the DPP-4 inhibitors. Another difference is that unlike the DPP-4 inhibitors, the GLP-1 agonists also slow gastric emptying and promote satiety.

Original languageEnglish (US)
Pages (from-to)S5-S9
JournalJournal of Family Practice
Volume59
Issue number9 SUPPL. 1
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Family Practice

Fingerprint Dive into the research topics of 'Pathophysiology of type 2 diabetes mellitus: Potential role of incretin-based therapies'. Together they form a unique fingerprint.

  • Cite this

    Campbell, R. K., Cobble, M. E., Reid, T. S., & Shomali, M. E. (2010). Pathophysiology of type 2 diabetes mellitus: Potential role of incretin-based therapies. Journal of Family Practice, 59(9 SUPPL. 1), S5-S9.